Gut microbe byproduct TMA boosts blood sugar control by turning down a key inflammatory switch
A microbial metabolite long linked to heart risk emerges as an unexpected ally against metabolic inflammation, showing how gut–host signaling can reset glucose regulation by targeting a single immune kinase.
Study: Inhibition of IRAK4 by microbial trimethylamine blunts metabolic inflammation and ameliorates glycemic control (https://www.nature.com/articles/s42255-025-01413-8). Image Credit: Ahmet Misirligul / Shutterstock
A recent Nature Metabolism study identifies a gut microbial metabolite that improves glycemic control and modulates innate-immune–driven inflammation in obese mice by targeting a central kinase in innate immune signaling.
Global diabetes burden and inflammatory processes
Diabetes, a chronic metabolic disorder marked by high blood glucose, has become a global public health crisis. The World Health Organization reports that roughly 529 million people live with diabetes worldwide, and about 1.6 million deaths occur each year due to this condition. Unhealthy lifestyles—poor diet and physical inactivity—are major factors driving the rise of metabolic diseases such as diabetes and obesity.
The gut microbiota—the trillions of microorganisms in the digestive tract—plays a pivotal role in fueling chronic, low-grade inflammation and insulin resistance, both hallmark features of diabetes. Evidence suggests that interactions between bacterial lipopolysaccharides (LPS) and dietary fats can trigger low-grade inflammation and insulin resistance by activating the toll-like receptor 4 (TLR4), a key component of the innate immune system.
Although several signaling molecules mediating gut microbial–host chemical communication have been identified, many details remain unclear about which microbial metabolites drive these processes.
Trimethylamine (TMA) is among the most abundant metabolites produced when gut bacteria metabolize dietary choline and carnitine. TMA is a precursor to trimethylamine N-oxide (TMAO), a compound known for its adverse cardiovascular effects. There is also evidence linking TMA to insulin resistance.
Related stories
- Blood sugar migration to saliva fuels cavity development in type 2 diabetes patients
- Dash diet reduces diabetes complications by targeting blood pressure, kidney health, and inflammation
- Chronic drinking weakens the blood–brain barrier through the gut
Given the potential role of TMA and related metabolites in cardiometabolic disease, this study investigated how TMA might relate to high-fat-diet–induced glucose intolerance, insulin resistance, and obesity-associated metabolic dysfunction.
How TMA interacts with IRAK4: experimental approach
Mice were fed a high-fat diet with either low or high choline content, alongside normally fed controls, to induce obesity and glucose intolerance and to examine how choline-driven TMA production influences these conditions.
Results showed that TMA reduced high-fat-diet–induced low-grade inflammation and insulin resistance by inhibiting interleukin-1 receptor-associated kinase 4 (IRAK4), a key kinase in the TLR pathway that detects danger signals from pathogens.
Both genetic silencing and chemical inhibition of IRAK4 produced similar improvements in metabolic and immune function in high-fat-diet–fed mice. This supports a novel role for TMA and its target kinase in immunometabolism.
Additionally, a single TMA dose significantly improved survival in mice subjected to lipopolysaccharide (LPS)–induced septic shock.
Choline intake, TMA production, and immune modulation
When mice were fed low- versus high-choline in high-fat diets, choline supplementation reduced high-fat-diet–induced inflammation. Further analysis revealed a 20-fold increase in circulating TMA levels in mice on a high-choline diet compared with those on a low-choline diet, indicating amplified microbial conversion of dietary choline into TMA.
These findings imply that TMA generated by gut microbes from dietary choline can act as a signaling molecule that modulates TLR signaling to improve glycemic control and dampen inflammatory responses in the host.
Context-dependent roles of TMA and TMAO
In the liver, TMA is converted to TMAO by flavin-containing monooxygenase 3 (FMO3). TMAO is a well-established cardiovascular risk factor, yet it has also shown potential benefits, such as reducing blood–brain barrier permeability in some contexts. Conversely, TMA has been reported to disrupt the blood–brain barrier. Overall, evidence suggests that TMAO’s detrimental effects may require underlying pathologies to become evident.
Some prior studies have indicated that choline-rich diets can impair glucose tolerance and pancreatic beta-cell function in mice by raising plasma TMAO levels, which contrasts with the current study’s findings. Taken together, these data suggest that TMA and TMAO can play opposing, context- and mechanism-dependent roles.
Mechanistic insights: TMA’s independent pathway
In the liver, TMA is converted to TMAO by FMO3, but inactivation of this enzyme, which raises TMA relative to TMAO, has been linked to various metabolic benefits. This suggests that the benefits seen with FMO3 inactivation are not solely due to TMAO depletion, pointing to an independent mechanism for TMA.
The current study shows that TMA directly binds to and inhibits IRAK4, a mechanism not shared by TMAO, highlighting a distinct pathway for TMA’s metabolic effects.
Implications for diet and future research
Overall, these findings lay a strong groundwork for future clinical trials exploring anti-diabetic effects and improvements in obesity-related metabolic dysfunction through dietary strategies that increase TMA bioavailability, while noting that human evidence remains primarily in vitro at this stage.
Journal reference:
Chilloux J. 2025. Inhibition of IRAK4 by microbial trimethylamine blunts metabolic inflammation and ameliorates glycemic control. Nature Metabolism. DOI: 10.1038/s42255-025-01413-8
https://www.nature.com/articles/s42255-025-01413-8
